> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Expanded Approval for Boehringer Asthma Therapy
- URL: https://www.fdaweb.com/fda-expanded-approval-for-boehringer-asthma-therapy/
- Published: 2017-02-16T12:00:00.000Z
- Updated: 2026-09-14T22:06:55.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137999

FDA has expanded the approval for Boehringer Ingelheim Pharmaceuticals’ asthma medication Spiriva Respimat for the long-term, once-daily maintenance treatment of asthma in people age six and older. The agency approved the supplemental NDA under a priority review, and it also granted pediatric exclusivity for the product based on the clinical trials conducted by the company. Data supporting approval came from the Phase 2 and Phase 3 UniTinA-asthma clinical development program, which included more than 6,000 patients at over 150 sites. Spiriva Respimat was approved 9/2015 for the long-term, once-daily, prescription maintenance treatment of asthma in people age 12 and older.